Currently, the safety, tolerability and efficacy of AAVrh10 intrathecal administration of anti-SOD1 microRNA to patients with SOD1 ALS mutations is being tested in the multi-center clinical trial APB-102 [132,133]. Here, SOD1 is linked to amyotrophic lateral sclerosis.